

Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

SIGA TECHNOLOGIES INC  
Form 8-K  
December 14, 2005

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15 (d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 13, 2005

SIGA TECHNOLOGIES, INC.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	0-23047 (Commission file number)	13-3864870 (I.R.S. employer identification no.)
-------------------------------------------------------------------------------	----------------------------------------	-------------------------------------------------------

420 Lexington Avenue, Suite 408 New York, New York (Address of principal executive offices)	10170 (Zip code)
------------------------------------------------------------------------------------------------------	---------------------

Registrant's telephone number, including area code: (212) 672-9100

-----  
Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any  
of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR  
230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR  
240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange  
Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange  
Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On December 13, 2005, SIGA Technologies, Inc., a Delaware corporation ("SIGA"), issued a press release pursuant to which SIGA announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application to begin Phase I clinical trials of SIGA-246, its lead smallpox drug. SIGA also announced that in order to expedite the program, the FDA granted SIGA-246 Fast-Track status.

A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

(c) Exhibits

Exhibit No. -----	Description -----
99.1	Press Release, dated December 13, 2005.

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGA TECHNOLOGIES, INC.

By: /s/ Thomas N. Konatich

-----  
Name: Thomas N. Konatich  
Title: Chief Financial Officer

Date: December 14, 2005

-3-